Cite
Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review
MLA
Yan Mao, et al. “Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer Responded Well to Abemaciclib and Exemestane after Palbociclib and Fulvestrant Failure: A Case Report and Literature Review.” Frontiers in Oncology, vol. 12, Jan. 2023. EBSCOhost, https://doi.org/10.3389/fonc.2022.1022913.
APA
Yan Mao, Meng Lv, Yongmei Wang, Weihong Cao, & Wenfeng Li. (2023). Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.1022913
Chicago
Yan Mao, Meng Lv, Yongmei Wang, Weihong Cao, and Wenfeng Li. 2023. “Hormone Receptor-Positive, HER2-Negative, Metastatic Breast Cancer Responded Well to Abemaciclib and Exemestane after Palbociclib and Fulvestrant Failure: A Case Report and Literature Review.” Frontiers in Oncology 12 (January). doi:10.3389/fonc.2022.1022913.